VEGFR3/Flt-4 Antibody (9D9) - Azide and BSA Free

Immunohistochemistry: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Saphenous vein wall harvested from a patient diagnosed with triple-vessel CAD. Histological sections of a graft wall obtained from a 71-year-old patient who developed early graft failure 11 months after coronary artery bypass grafting. VEGFR-3 (b) is shown to be expressed by immunohistochemical staining in smooth muscle cells of the tunica media (TM) and is strongly present in endothelial cells of the tunica intima (TI). Image collected and cropped by CiteAb from the following publication (//link.springer.com/10.1007/s00380-018-1158-9) licensed under a CC-BY license.

Western Blot: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Analysis using recombinant human soluble VEGF Receptor 3 as target.

Flow Cytometry: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Fig. 1: Flow analysis of VEGFR-3/FLT4 expression in primary human dermal lymphatic endothelial cells (HDLEC).

Flow Cytometry: VEGFR3/Flt-4 Antibody (9D9) [NBP1-18651] - Fig. 1: Flow analysis of VEGFR-3/FLT4 expression in primary human dermal mivrovascular endothelial cells (HDMVEC) and human umbilical vein endothelial cells (HUVEC). There is only a very weak expression of VEGFR-3/FLT4 detectable in the HUVECs but a strong one in the HDMVEC.

Immunohistochemistry: VEGFR3/Flt-4 Antibody (9D9) - Azide and BSA Free [NBP1-18651] - Saphenous vein wall harvested from a patient diagnosed with double-vessel CAD showing immunohistochemical staining. VEGF-C (a) & VEGFR-3 (b) reactivity in a graft wall obtained from a 67-year-old patient who developed the early graft restenosis within 7 months after coronary artery bypass grafting (the same patient as mentioned in Fig. 6). VEGF-C is localized exclusively within individual smooth muscle cells of the tunica media (TM). Cells with positive VEGFR-3 expression are situated in endothelial cells of the tunica intima (TI). c Negative control. TA tunica adventitia Image collected & cropped by CiteAb from the following publication (//link.springer.com/10.1007/s00380-018-1158-9), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: VEGFR3/Flt-4 Antibody (9D9) - Azide and BSA Free [NBP1-18651] - Immunohistochemical staining of an internal thoracic artery & saphenous vein wall harvested from a patient with no evidence of luminal stenosis 12 months after CABG. Immunohistochemical staining of VEGF-C (a) & CAV2 (b) in an internal thoracic artery (ITA) graft & VEGFR-3 (c) in saphenous vein (SV) transplant harvested from a 65-year-old patient diagnosed with triple-vessel CAD. Note that lack of CAV2 expression within smooth muscle cells (SMC) in ITA wall is accompanied by VEGF-C positive expression in the same area. In SV tissue sample harvested from the same patient, no VEGRR-3 expression was found. d Negative control. TI tunica intima, TM tunica media, TA tunica adventitia Image collected & cropped by CiteAb from the following publication (//link.springer.com/10.1007/s00380-018-1158-9), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

• Reactivity: Hu
• Applications: WB, ELISA, Flow, IHC, CyTOF-ready
• Clone: 9D9
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: Azide and BSA Free
• Concentration: LYOPH

VEGFR3/Flt-4 Antibody (9D9) - Azide and BSA Free Summary

• Description: Clone #1 changed to 9D9 as a more unique identifier.
• Immunogen: Recombinant human soluble VEGFR-3/FLT-4
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: FLT4
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • ELISA 1-5ug/ml
  • Flow Cytometry 1-5 ug/ml
  • Immunohistochemistry 1-10ug/ml
  • Western Blot 1-5ug/ml
• Application Notes: This antibody is CyTOF ready.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: Protein G purified
• Reconstitution Instructions: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. Please note the sample size of this product will be provided in reconstituted liquid form.

Alternate Names for VEGFR3/Flt-4 Antibody (9D9) - Azide and BSA Free

• EC 2.7.10
• EC 2.7.10.1
• FLT4
• Flt-4
• fms-related tyrosine kinase 4
• LMPH1A
• PCLFLT41
• soluble VEGFR3 variant 1
• soluble VEGFR3 variant 2
• soluble VEGFR3 variant 3
• Tyrosine-protein kinase receptor FLT4
• vascular endothelial growth factor receptor 3
• VEGF R3
• VEGFR3
• VEGFR-3
• VEGFR3Fms-like tyrosine kinase 4

Background

Vascular endothelial growth factors (VEGFs) are a family of closely related growth factors having a conserved pattern of eight cysteine esidues and sharing common VEGF receptors. VEGFs stimulate the proliferation of endothelial cells, induce angiogenesis, and increase vascular permeability in both large and small vessels. The mitogenic activity of VEGFs appears to be mediated by specific VEGF receptors. VEGF Receptor 3 is one of the five receptor tyrosine kinases (RTKs) (VEGF Receptor 1/Flt1, VEGF Receptor 2/KDR/Flk1, VEGF Receptor 3/Flt4, tie1 and tek/tie2) whose expression is almost exclusively restricted to endothelial cells.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VEGFR3/Flt-4 Antibody (NBP1-18651)(2)

Publications using NBP1-18651

• Agarwal S, Harter Z, Krishnamachary B, et al. EXPRESS: Sugen-Morphine (SuMo) model of pulmonary arterial hypertension Pulm Circ 2019-12-13 [PMID: 32110385] (IHC-P, Rat)
• Podemska-Jedrzejczak Z, Malinska A, et al. Vascular restenosis in coronary artery bypass grafting might be associated with VEGF-C/VEGFR-3 signaling pathway. Heart Vessels 2018-09-01 [PMID: 29557990] (IF/IHC, Human)

Bioinformatics

• Gene Symbol: FLT4
• Entrez:
  • 2324(Human)